China SXT Pharmaceuticals, Inc. (SXTC)

USD 0.34

(-1.79%)

Market Cap (In USD)

1.16 Million

Revenue (In USD)

1.92 Million

Net Income (In USD)

-3.09 Million

Avg. Volume

642.77 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.33-6.39
PE
-
EPS
-
Beta Value
1.163
ISIN
VGG2161P1403
CUSIP
G2161P108
CIK
1723980
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Feng Zhou
Employee Count
-
Website
https://www.sxtchina.com
Ipo Date
2019-01-04
Details
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.